Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We report the case of an 82-year-old male with a history of bronchiectasis, asthma, and atrial fibrillation, who presented with progressive exertional dyspnoea, peripheral oedema, and recurrent heart failure exacerbations. Initial management targeted presumed pulmonary decompensation. Elevated natriuretic peptides, echocardiographic evidence of concentric left ventricular hypertrophy with preserved ejection fraction, and progressive conduction abnormalities prompted further evaluation. A 99mTc-DPD scintigraphy scan revealed Perugini grade 3 myocardial uptake consistent with wild-type transthyretin (ATTRwt) cardiac amyloidosis. Serum and urine studies excluded light-chain amyloidosis. Despite the presence of classical 'red flag' features, including atrial fibrillation, carpal tunnel syndrome, and unexplained left ventricular hypertrophy, diagnosis was significantly delayed by approximately 18 months, from initial symptom onset to definitive diagnosis, during which recurrent hospitalisations and progressive functional decline occurred. Earlier features were overlooked due to the attribution of symptoms to coexistent pulmonary disease and chronic kidney dysfunction. This case highlights the diagnostic challenges posed by ATTRwt, particularly in multimorbid older adults. Overlapping features with respiratory and renal pathology, as well as age-associated cardiovascular changes, obscure the clinical picture. Awareness of hallmark extracardiac features, systematic use of cardiac imaging, and prompt nuclear scintigraphy are essential for timely diagnosis. Early identification may enable consideration of disease-modifying therapy and improved symptom management.

Original publication

DOI

10.7759/cureus.89851

Type

Journal article

Journal

Cureus

Publication Date

08/2025

Volume

17

Keywords

99mtc-dpd scintigraphy, cardiac amyloidosis, conduction abnormalities, heart failure with preserved ejection fraction (hfpef), transthyretin (attrwt)